CTLA4 and cancer: Recently, cancer immunotherapies, including antibodies targeting immune checkpoint molecules, such as PD-1, PD-L1 and CTLA-4, have emerged as an unprecedented breakthrough for the treatment of cancer that can induce long-term tumor regression.